|
ニシムラ カツジ
NISHIMURA Katsuji
西村 勝治 所属 医学部 医学科（東京女子医科大学病院） 職種 教授・基幹分野長 |
|
| 論文種別 | 原著 |
| 言語種別 | 英語 |
| 査読の有無 | 査読あり |
| 表題 | Role of Serum Lithium Concentrations in Predicting Hyperparathyroidism and Hypercalcemia. |
| 掲載誌名 | 正式名：International journal of endocrinology 略 称：Int J Endocrinol ISSNコード：16878337/16878337 |
| 掲載区分 | 国外 |
| 巻・号・頁 | 2025,pp.6497151 |
| 著者・共著者 | Noriyoshi Takano†, Satoshi Morimoto*, Hiroyuki Muraoka, Ken Inada, Katsuji Nishimura, Atsuhiro Ichihara |
| 発行年月 | 2025 |
| 概要 | Purpose: Lithium (Li), which is extensively used in the treatment of mood disorders such as bipolar disorder, has been associated with hyperparathyroidism. However, the relationship between the serum Li concentration and hyperparathyroidism remains unclear. This study aimed (1) to investigate the incidence of hyperparathyroidism and hypercalcemia in consecutive patients treated with Li, (2) to assess the correlation between serum Li concentration and hyperparathyroidism/hypercalcemia, and (3) to establish cutoff values for predicting hyperparathyroidism and hypercalcemia based on serum Li concentration. Methods: This retrospective cross-sectional study was conducted at the Department of Psychiatry and Department of Medicine at Tokyo Women's Medical University. Ninety-seven consecutive individuals without renal impairment and with an estimated glomerular filtration rate (eGFR) equal to or greater than 45 mL/min/1.73 m2 were included. Results: Hyperparathyroidism and hypercalcemia were observed in 35.1% and 9.3% of the patients on Li, respectively. The serum Li concentration showed a significant positive correlation with hyperparathyroidism and hypercalcemia, independent of other factors. The cutoff values for predicting hyperparathyroidism and hypercalcemia were 0.52 and 0.62 mEq/L, respectively. Conclusions: This study confirmed that the high incidence of hyperparathyroidism and hypercalcemia in patients treated with Li. Clinicians should be aware that Li treatment may induce hyperparathyroidism, and a serum Li concentration exceeding 0.52 mEq/L may pose an increased risk. Monitoring serum calcium and Li concentrations is recommended in patients undergoing Li treatment. |
| DOI | 10.1155/ije/6497151 |
| PMID | 40747083 |